Skip to main content
رجوع
VRTX logo

Vertex Pharmaceuticals Incorporated

جودة البيانات: 100%
VRTX
NASDAQ Healthcare Biotechnology
KWD 451.24
▼ KWD 2.77 (-0.61%)
القيمة السوقية: 114.61B
نطاق اليوم
KWD 450.97 KWD 463.78
نطاق 52 أسبوعًا
KWD 362.50 KWD 513.98
حجم التداول
1,152,006
متوسط 50 يوم / 200 يوم
KWD 469.18 / KWD 438.51
الإغلاق السابق
KWD 454.00

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 29.0 0.4
P/B 6.1 2.9
ROE % 22.5 3.7
Net Margin % 32.7 3.8
Rev Growth 5Y % 12.4 10.0
D/E 0.2 0.2

Insider Trading Activity

Buy ratio (90d) 0.0%
20 transactions
Date Insider Type Shares Price Value
Mar 13, 2026
Bozic Carmen
EVP and CMO
sell 2,329 KWD 481.790 KWD 1,122,089
Mar 2, 2026
Liu Joy
EVP and Chief Legal Officer
sell 892 KWD 495.960 KWD 442,396
Feb 25, 2026
Biller Jonathan
EVP and Chief Legal Officer
sell 945 KWD 486.350 KWD 459,601
Feb 25, 2026
McKechnie Duncan
EVP, Chief Commercial Officer
sell 4,910 KWD 486.350 KWD 2,394,365
Feb 24, 2026
Biller Jonathan
EVP and Chief Legal Officer
other 1,144 KWD 485.110 KWD 554,966
Feb 24, 2026
LEIDEN JEFFREY M
Executive Chairman
other 3,547 KWD 485.110 KWD 1,720,685
Feb 24, 2026
McKechnie Duncan
EVP, Chief Commercial Officer
other 873 KWD 485.110 KWD 423,501
Feb 24, 2026
Kewalramani Reshma
CEO & President
other 4,981 KWD 485.110 KWD 2,416,333
Feb 24, 2026
Bozic Carmen
EVP and CMO
other 1,453 KWD 485.110 KWD 704,865
Feb 17, 2026
McKechnie Duncan
EVP, Chief Commercial Officer
grant 4,962
Feb 17, 2026
McKechnie Duncan
EVP, Chief Commercial Officer
other 1,148 KWD 483.750 KWD 555,345
Feb 13, 2026
Kewalramani Reshma
CEO & President
other 13,041 KWD 487.760 KWD 6,360,878
Feb 10, 2026
WAGNER CHARLES F JR
EVP, CO & FO
other 3,045 KWD 468.410 KWD 1,426,308
Feb 10, 2026
Sachdev Amit
EVP Chief Patient & Ext Af Off
other 2,057 KWD 468.410 KWD 963,519
Jan 22, 2026
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
grant 11,749
Jan 6, 2026
WAGNER CHARLES F JR
EVP, CO & FO
other 19,064 KWD 189.380
Jan 6, 2026
WAGNER CHARLES F JR
EVP, CO & FO
sell 9,532 KWD 461.000 KWD 4,394,252
May 1, 2025
SACHS BRUCE I
Director
grant 2,398
May 1, 2025
CARNEY LLOYD
Director
grant 796
Apr 15, 2025
SACHS BRUCE I
Director
grant 95 KWD 497.510 KWD 47,263

النقاط الرئيسية

Revenue grew 12.37% annually over 5 years — strong growth
ROE of 22.54% indicates high profitability
Net margin of 32.74% shows strong profitability
Debt/Equity of 0.21 — conservative balance sheet
Generating 3.19B in free cash flow
Cash machine — converts 80.79% of earnings into free cash flow

النمو

Revenue Growth (5Y)
12.37%
Revenue (1Y)9.57%
Earnings (1Y)N/A
FCF Growth (3Y)-1.31%

الجودة

Return on Equity
22.54%
ROIC15.84%
Net Margin32.74%
Op. Margin39.43%

الأمان

Debt / Equity
0.21
Current Ratio2.90
Interest Coverage357.95

التقييم

P/E Ratio
28.99
P/B Ratio6.14
EV/EBITDA23.82
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9.57% Revenue Growth (3Y) 10.61%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 4.51%
Revenue Growth (5Y) 12.37% Earnings Growth (5Y) 13.98%
Profitability
Revenue (TTM) 12.07B Net Income (TTM) 3.95B
ROE 22.54% ROA 15.12%
Gross Margin 85.03% Operating Margin 39.43%
Net Margin 32.74% Free Cash Flow (TTM) 3.19B
ROIC 15.84% FCF Growth (3Y) -1.31%
Safety
Debt / Equity 0.21 Current Ratio 2.90
Interest Coverage 357.95 Dividend Yield 0.00%
Valuation
P/E Ratio 28.99 P/B Ratio 6.14
P/S Ratio 9.49 PEG Ratio -0.03
EV/EBITDA 23.82 Dividend Yield 0.00%
Market Cap 114.61B Enterprise Value 113.41B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 12.07B 11.02B 9.87B 8.93B 7.57B
Net Income 3.95B -535.60M 3.62B 3.32B 2.34B
EPS (Diluted) 15.32 -2.08 13.89 12.82 9.01
Gross Profit 10.27B 9.49B 8.61B 7.85B 6.67B
Operating Income 4.76B -232.90M 3.83B 4.31B 2.78B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 26.14B 22.53B 22.73B 18.15B 13.43B
Total Liabilities 7.48B 6.12B 5.15B 4.24B 3.33B
Shareholders' Equity 18.67B 16.41B 17.58B 13.91B 10.10B
Total Debt 3.88B 1.75B 808.40M 899.70M 967.40M
Cash & Equivalents 5.09B 4.57B 10.37B 10.50B 6.80B
Current Assets 11.20B 9.60B 14.14B 13.23B 9.56B
Current Liabilities 3.86B 3.56B 3.55B 2.74B 2.14B